Physician

Sriram Sambasivan, M.D.

According to 2025 Medicare claims, Sriram Sambasivan, M.D. (NPI: 1356350821) practices nephrology in the Redding, CA market, with the plurality of this provider's patient population coming from Shasta, CA. This provider's primary affiliated billing organization is SHASTA CRITICAL CARE SPECIALISTS MEDICAL CLINIC, INC. (NPI: 1245249770; TIN: 20-1811944) and primary practice location at 96001-0913.

Sambasivan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,174 traditional Medicare patients, billed 4,552 HCPCS/CPT codes, and received $561,330 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 1,760 prescription claims across 359 beneficiaries totaling $174,196 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 309 claims. Open Payments data shows 3 records totaling $154. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $109,647 and ending at $174,196. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $5,541 to $7,524.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,126	4,029	$427,754
2016	1,160	4,464	$459,267
2017	1,223	4,573	$520,243
2018	1,124	4,386	$512,088
2019	1,137	4,283	$526,655
2020	1,080	4,222	$507,511
2021	1,239	4,477	$560,672
2022	1,079	3,856	$500,796
2023	1,162	3,755	$452,938
2024	1,174	4,552	$561,330

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	238	1,362	$109,647
2016	249	1,405	$119,825
2017	262	1,452	$124,866
2018	276	1,797	$128,359
2019	286	1,879	$101,627
2020	275	1,599	$83,033
2021	288	1,698	$115,543
2022	221	1,257	$54,725
2023	254	1,271	$107,639
2024	359	1,760	$174,196

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	92	$7,956
2016	N/R	101	$6,287
2017	N/R	122	$12,600
2018	N/R	221	$16,863
2019	N/R	269	$18,724
2020	N/R	256	$11,747
2021	N/R	235	$9,025
2022	11	295	$7,495
2023	40	382	$12,519
2024	38	309	$6,115

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	227	637	$268
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	248	265	$131
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	483	713	$93
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	331	807	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	240	276	$59

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	64	2,340	$40,303
Jardiance	Empagliflozin	38	1,560	$27,681
Lokelma	Sodium Zirconium Cyclosilicate	47	1,604	$14,683
Sevelamer Carbonate	Sevelamer Carbonate	17	510	$3,585
Prosol	Parenteral Amino Acid 20% No.1	14	92	$2,101

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7507	Tacrolimus, immediate release, oral, 1 mg	N	12	70	$1,439
J7520	Sirolimus, oral, 1 mg	N	N/R	11	$1,230
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	12	79	$1,104
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	14	64	$1,092
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	38	$622

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$154	Aurinia Pharma U.S., Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sriram Sambasivan, M.D.?

Tedicare shows public-source Medicare data for Sriram Sambasivan, M.D. (NPI 1356350821), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sriram Sambasivan, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Sriram Sambasivan, M.D.?

Sriram Sambasivan, M.D. is linked to SHASTA CRITICAL CARE SPECIALISTS MEDICAL CLINIC, INC. (billing NPI 1245249770) in the available physician profile data.

Does Sriram Sambasivan, M.D. have Open Payments data?

Sriram Sambasivan, M.D. has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.